Metabolic dysfunction-associated steatohepatitis (MASH): Difference between revisions

Line 17: Line 17:
*[[Hemochromatosis]]
*[[Hemochromatosis]]
*[[Hepatocellular carcinoma]]
*[[Hepatocellular carcinoma]]
*[[CHF]] (right heart failure]]
*[[CHF]] (right heart failure
 
{{Hepatomegaly DDX}}


==Evaluation==
==Evaluation==

Revision as of 20:47, 7 September 2022

Background

Stages of non-alcoholic fatty liver disease, progressing from healthy, to steatosis (fat accumulation), inflammation, fibrosis and cirrhosis.
  • Fatty liver disease due to causes other than excessive alcohol
  • Associated with insulin resistance and metabolic syndrome

Clinical Features

Differential Diagnosis

Hepatic Dysfunction

Infectious

Neoplastic

Metabolic

Biliary

  • Biliary cirrhosis

Drugs

Miscellaneous

Evaluation

  • LFTs, CBC
  • RUQ US
  • Outpatient elastography/Fibroscan

Management

  • Treat complications of portal hypertension, if present
  • Counsel on weight loss, increased coffee consumption
  • Vitamin E if known F2 fibrosis

Disposition

  • Discharge unless complications

See Also

External Links

References

  1. Tintanelli's